Long-Acting Injectable Antipsychotics for the Maintenance Treatment of Bipolar Disorder

  title={Long-Acting Injectable Antipsychotics for the Maintenance Treatment of Bipolar Disorder},
  author={Alexandre Duarte Gigante and Beny Lafer and Lakshmi N. Yatham},
  journal={CNS Drugs},
Depot antipsychotics have been used as a strategy to reduce non-adherence to medications in schizophrenia and bipolar disorder (BD). This article reviews the literature on the efficacy and safety of first- and second-generation depot antipsychotics (FGDA and SGDA, respectively) for the maintenance treatment of BD. Although FGDA have been studied in BD, they have not been approved for use in this disease. Among the SGDA, only depot risperidone has been studied and approved for the maintenance… 
A Systemic Review and Experts’ Consensus for Long-acting Injectable Antipsychotics in Bipolar Disorder
  • Y. Chou, Po-Chung Chu, Y. Yen
  • Medicine, Psychology
    Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology
  • 2015
LAI antipsychotic use was recommended in BD patients with the following characteristics: multiple episodes and low adherence; seldom yet serious episodes; low adherence potential per a physician’s clinical judgment; preference for injectable agents over oral agents; and multiple oral agent users still experiencing residual symptoms.
Long Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Bipolar Disorder
The results of studies on the use of LAIAs in patients with first-episode schizophrenia indicate thatLAIAs have advantageous in preventing relapse and re-hospitalization compared to oral antipsychotics.
Long-Acting Injectable Second-Generation/Atypical Antipsychotics for the Management of Bipolar Disorder: A Systematic Review
Overall, second-generation LAI antipsychotics were found to be well tolerated and effective for treatment of manic symptoms and preventing mood recurrences in adults with bipolar disorder and may be a safe and effective alternative to oral medications in the management of bipolar disorder.
Effect of long acting injectable antipsychotics on course and hospitalizations in bipolar disorder – a naturalistic mirror image study
LAI-AP use may have positive effect on course for selected patients with a long history of bipolar disorder, as compared with other long-acting injectable antipsychotics.
Efficacy and safety of long acting injectable atypical antipsychotics: a review.
The literature on LAI atypical antipsychotics will be reviewed and practical advice will be given concerning the use of these drugs in the clinical practice.
Efficacy and safety of second-generation antipsychotic long-acting injections (SGA LAIs) in maintenance treatment of bipolar disorder: protocol for a systematic review and meta-analysis
This study aims to systematically review safety and efficacy of second-generation antipsychotics (SGA) LAIs in the maintenance treatment of bipolar disorder and includes only randomised controlled trials comparing SGALAIs in bipolar.
Ef fi cacy and safety of second-generation antipsychotic long-acting injections ( SGA LAIs ) in maintenance treatment of bipolar disorder : protocol for a systematic review and meta-analysis
This study aims to systematically review safety and efficacy of SGA LAIs in the maintenance treatment of bipolar disorder and will include only randomised controlled trials comparing SGALAIs in bipolar.
Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder – expert consensus survey part 2
Advice on initiating and maintaining long-acting injectable antipsychotics in individuals with schizophrenia/schizoaffective or bipolar disorder may aid clinicians in their decisions regarding initiating/maintaining LAIs.


Risperidone long-acting injectable for maintenance therapy in bipolar disorder: An open-label pilot study
Patients with bipolar disorder showed maintained symptom control over a 6-month treatment period with RLAI, and controlled studies in this population are required.
Psychopharmacology and adverse effects of antipsychotic long-acting injections: A review
  • David Taylor
  • Medicine, Psychology
    British Journal of Psychiatry
  • 2009
All LAIs offer the prospect of assured adherence but their use is complicated by adverse effects, complex pharmacokinetics and confusion over dose–response relationships, and by the lack of data establishing clear dose requirements.
[Efficacy and safety of long-acting injectable risperidone in maintenance phase of bipolar and schizoaffective disorder].
LAIR could be an effective maintenance therapy for bipolar and schizoaffective patients with poor compliance to oral treatment.
Depot risperidone in the outpatient management of bipolar disorder: a 2-year study of 10 patients
Clinicians may consider risperidone Consta as an option in patients with refractory bipolar illness, including those with a predominantly depressive course, and particularly in patients' nonadherence with prescribed medications.
A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone
  • E. Vieta, E. Nieto, P. Bonet
  • Psychology, Medicine
    The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry
  • 2008
This observational long-term study provides support to long-acting injectable risperidone being effective for the maintenance treatment of mania and improving treatment adherence, reducing relapses and re-hospitalization rates.
Risks versus benefits of different types of long-acting injectable antipsychotics.
  • J. McEvoy
  • Psychology, Medicine
    The Journal of clinical psychiatry
  • 2006
Since their introduction into clinical practice in the early 1960s, long-acting depot antipsychotics have been widely used as maintenance therapy for patients with schizophrenia. The improved
Usefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorder
Risperidone Long-Acting Injectable Monotherapy in the Maintenance Treatment of Bipolar I Disorder
Depot Antipsychotics in the Prophylaxis of Bipolar Affective Disorder
Departure antipsychotic medication may be a useful prophylactic treatment for certain patients with bipolar affective disorder.
Depot antipsychotics in bipolar affective disorder
Prophylactic treatment with depot antipsychotic drugs is likely to be of benefit in patients with bipolar illness who experience frequent manic episodes despite treatment with lithium and/or carbamazepine.